Replimune Group (NASDAQ:REPL) PT Raised to $50.00

Replimune Group (NASDAQ:REPL) had its price objective boosted by Barclays from $29.00 to $50.00 in a research report report published on Thursday, The Fly reports. Barclays currently has an overweight rating on the stock.

A number of other research analysts have also recently commented on the stock. Zacks Investment Research upgraded shares of Replimune Group from a sell rating to a hold rating in a research note on Saturday, October 10th. SVB Leerink raised their price target on shares of Replimune Group from $27.00 to $44.00 and gave the stock an outperform rating in a research note on Thursday. BidaskClub upgraded shares of Replimune Group from a sell rating to a hold rating in a research note on Tuesday, September 1st. Chardan Capital raised their price target on shares of Replimune Group from $30.00 to $48.00 and gave the stock a buy rating in a research note on Wednesday. Finally, HC Wainwright upgraded shares of Replimune Group from a neutral rating to a buy rating and raised their price target for the stock from $25.00 to $54.00 in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $42.06.

REPL stock opened at $40.98 on Thursday. Replimune Group has a twelve month low of $8.58 and a twelve month high of $46.30. The company has a market cap of $1.65 billion, a PE ratio of -24.69 and a beta of 3.20. The business’s 50-day simple moving average is $24.54 and its 200 day simple moving average is $20.54. The company has a quick ratio of 22.54, a current ratio of 22.54 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last released its earnings results on Friday, August 7th. The company reported ($0.44) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.44). On average, equities research analysts anticipate that Replimune Group will post -1.78 EPS for the current year.

In related news, insider Pamela Esposito sold 16,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $32.90, for a total value of $526,400.00. Following the completion of the transaction, the insider now owns 128,700 shares in the company, valued at approximately $4,234,230. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Colin Love sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.44, for a total transaction of $351,600.00. Following the completion of the transaction, the chief operating officer now owns 1,042,488 shares of the company’s stock, valued at approximately $24,435,918.72. The disclosure for this sale can be found here. Insiders sold 36,000 shares of company stock valued at $1,013,250 in the last quarter. 50.90% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of REPL. Bank of New York Mellon Corp raised its position in Replimune Group by 6.7% in the 1st quarter. Bank of New York Mellon Corp now owns 33,925 shares of the company’s stock worth $338,000 after purchasing an additional 2,122 shares during the last quarter. State Street Corp raised its position in Replimune Group by 9.5% in the 1st quarter. State Street Corp now owns 213,465 shares of the company’s stock worth $2,128,000 after purchasing an additional 18,484 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Replimune Group by 35.7% during the 1st quarter. Victory Capital Management Inc. now owns 448,386 shares of the company’s stock worth $4,470,000 after acquiring an additional 118,002 shares during the period. BNP Paribas Arbitrage SA grew its holdings in Replimune Group by 119.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,071 shares of the company’s stock worth $41,000 after acquiring an additional 2,212 shares during the period. Finally, Nuveen Asset Management LLC grew its holdings in Replimune Group by 267.0% during the 1st quarter. Nuveen Asset Management LLC now owns 165,521 shares of the company’s stock worth $1,650,000 after acquiring an additional 120,425 shares during the period. Hedge funds and other institutional investors own 60.86% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

See Also: How is the S&P 500 index different from the DJIA?

The Fly

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.